Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tris Pharma Inc.
Headquarters: Monmouth Junction, NJ, United States of America
Website: http://www.trispharma.com
Year Founded: 2000
Status: Private
BioCentury | Sep 18, 2024
Management Tracks
New CEOs at Nura, IMU
Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | May 31, 2024
Data Byte
FDA’s May approvals: an mRNA RSV vax, a bispecific and biosimilars
Moderna’s mResvia is its first mRNA vaccine approved outside COVID-19 pandemic
BioCentury | Jan 24, 2024
Management Tracks
Markison to succeed Heino as Lantheus CEO
Plus: Lisa Olson becomes CEO of Enthera, and updates from Bayer, Neumora, PDS and more
BioCentury | Nov 1, 2023
Management Tracks
Genentech’s Hardy to become CEO at BioMarin
Plus: BMS CEO Boerner appointed chair, and updates from Storm, Amarin, CTRL, Lakewood, Vesica and RS
BioCentury | May 5, 2023
Management Tracks
Walensky resigning as CDC director
Plus: Riva to lead Transgene as CEO and updates from Aerami, Ginkgo and Tris
BioCentury | Apr 30, 2021
Deals
April 29 Quick Takes: Illumina pushes back on EC review of Grail deal, donates tools to global initiative; plus Zhaoke, Sera, Ardelyx, Protalix-Chiesi, Moderna, Phathom, Tris-Park and more
Following last month’s 4-0 vote by the FTC to challenge Illumina’s pending $7.1 billion acquisition of Grail, the company announced that it filed an action in the General Court of
Items per page:
1 - 10 of 46